ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Clinicopathological characteristics, diagnostic challenges, and systemic implications of metastatic tumors to the eyelid: a systematic review.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic tumors to the eyelid are rare but clinically significant, often indicating advanced systemic malignancy or presenting as the first sign of an occult primary. Histopathology is the diagnostic cornerstone, yet the spectrum of clinicopathological patterns, immunohistochemistry, and common diagnostic pitfalls has not been systematically synthesized at the patient level.
methodsWe conducted a PRISMA 2020-compliant systematic review (protocol registered on the Open Science Framework). PubMed/MEDLINE, Embase, and Scopus were searched on 7 March 2026 without date restrictions, supplemented by Google Scholar citation tracking. Case reports and case series of histopathologically confirmed eyelid metastases were eligible. We performed a descriptive case-level systematic synthesis; proportions are reported with 95% Wilson confidence intervals. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports.
resultsSeventy-three studies (95 patients; 52/95, 54.7% female; median age 61 years, range 21-92) were included. Breast carcinoma was the most frequent primary site (39/95; 41.1%), followed by gastrointestinal tumors (15/95; 15.8%), renal cell carcinoma (9/95; 9.5%), and lung carcinoma (8/95; 8.4%). Metachronous presentation predominated (58/92; 63.0%; median interval 36 months, range 2-288), followed by synchronous (27/92; 29.3%) and occult presentation (7/92; 7.6%). Among 62 patients with documented preoperative impressions, 41/62 (66.1%) received a benign misdiagnosis; pyogenic granuloma was the most frequent mimic. Immunohistochemistry was reported in 61/73 studies (83.6%). BAP1 loss was observed in 2 of 3 evaluable uveal melanoma cases and was intact in all 6 cutaneous melanoma cases [18, 20]. Overall, 61/89 (68.5%; 95% CI 58.6-77.0%) had synchronous distant organ metastases at eyelid biopsy; eyelid biopsy identified an occult primary in 11/95 (11.6%) and altered oncologic management in 13/95 (13.7%).
conclusionsEyelid metastases commonly mimic benign conditions, supporting a low threshold for biopsy of atypical or refractory lesions. Site-directed immunohistochemistry, including BAP1 for melanoma subtype attribution, can be diagnostically informative and should inform staging and management decisions.
Indexed as
Identifiers
42603175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.